We aimed to measure the prevalence of physical inactivity (PI) during leisure time and to identify variables associated with it in a southern Brazilian adult population. A population-based cross-sectional study was carried out, covering a multiple-stage sample of 1,968 subjects aged 20-69 years. Weekly participation in leisure-time physical activity was addressed. For each activity, energy expenditure was calculated using data on duration, metabolic equivalent, and body weight. Energy expenditures of individual activities were summed to give a weekly total. PI was defined as fewer than 1,000 kilocalories per week. The prevalence of PI was 80.7% (95%CI: 78.9-82.4). After adjusted analyses, the following variables were positively associated with the outcome: female gender, age, living with a partner, and smoking. Schooling and economic status were inversely associated with PI. Chronically undernourished individuals were significantly more likely to be inactive. We found no differences according to skin color or alcohol consumption. In conclusion, the prevalence of PI in this adult population was higher than in populations from developed countries, but the associated variables were similar.

A qualidade de vida (QV) de mulheres com câncer de mama pode sofrer muitas alterações, dessa forma, é essencial encontrar fatores que auxiliem na melhora da QV desses indivíduos. O objetivo deste estudo é avaliar o impacto da atividade física na QV das pacientes com câncer de mama e verificar se os domínios da QV diferem em função da frequência de atividade física semanal. Trata-se de um estudo transversal, cuja população constituiu-se de 272 mulheres portadoras de câncer de mama. A QV foi avaliada por meio do questionário WHOQOL-Bref e as demais variáveis foram respondidas em questionário desenvolvido à parte. As mulheres que realizavam atividade física de forma regular obtiveram melhores pontuações significativas na QV nos domínios global (74,5 vs 67,8; p=0,001), físico (66,0 vs 57,3; p=0,001), meio ambiente (69,5 vs 64,1; p=0,001) e psicológico (72,4 vs 66,4; p=0,001). Em relação à frequência de atividade física por semana, as melhores médias de atividade física foram encontradas na faixa de realização de atividade três vezes na semana nos domínios global (79,5; p=0,01), físico (68,2; p=0,03) e meio ambiente (74,3; p=0,002). Dessa maneira, pode-se inferir que a realização de atividade física de forma regular é benéfica para a QV de mulheres com câncer de mama.

Por meio de estudo transversal de base populacional, incluindo pessoas de ambos os sexos, de 20 a 69 anos, residentes na zona urbana de Pelotas, Rio Grande do Sul, Brasil, objetivou-se verificar características associadas a consultas médicas ambulatoriais acima da média. A média de consultas, com médico, no último ano foi 3,2, com desvio padrão 5,5. A análise foi realizada considerando-se dois desfechos: indivíduos com mais de oito consultas médicas por ano (um desvio padrão acima da média); e mais de 14 consultas (dois desvios padrões acima da média). Entre 1.962 pessoas, 183 (9,3%) consultaram mais que oito vezes durante o ano. A regressão logística mostrou que estavam associadas as variáveis: sexo, idade, diabetes mellitus, hipertensão arterial, bronquite crônica, distúrbios psiquiátricos menores e hospitalizações no último ano. Encontraram-se 57 (2,9%) indivíduos com mais de quatorze consultas médicas durante o ano. Na regressão logística, foram encontradas diferenças para sexo, hipertensão arterial, distúrbios psiquiátricos menores e hospitalizações no último ano. A elevada procura por serviços de saúde nem sempre significa inadequação, e sua restrição pode resultar em políticas que restrinjam o acesso aos cuidados, implicando sofrimento para pacientes em condições graves.

4425 Adherence to imatinib therapy has proven to be a major determinant of treatment results, but the degree of impact and the determinants of nonadherence are still contradictory. There is no information regarding adherence to imatinib therapy in the Brazilian public health system. The aims of this study were to identify the characteristics related to treatment interruptions and nonadherence and to examine how these interruptions affect treatment responses and survival. Materials and Methods We conducted a retrospective study in a cohort of patients (pts) with CP-CML enrolled in 14 Hematology centers in South Brazil. All pts received imatinib 400mg as first or second-line therapy. Early-imatinib treatment was considered when imatinib started before 12 months (mo) from diagnosis. Patient evaluation and response criteria followed the ELN recommendations. The ACE-27 (Adult Comorbidity Evaluation-27) is a 27 item comorbidity index for patients with cancer and assign weights from 1 to 3 based on the dysfunction grade of each condition (mild, moderate and severe, respectively). An ACE-27 score was applied to each patient. Imatinib suspensions were considered if superior to 20 days at any point during therapy. Two levels of analysis were performed: all kinds of interruptions (nonadherence and toxicity) and only nonadherence ones. Information for nonadherence was taken from medical and pharmacy registers (pt self-report, missing scheduled appointments and pill counts). Results We analyzed data from 185 pts with CP-CML diagnosed since 1990. The median age at diagnosis was 48 yr (4 – 85) and 55% were male. The median time from diagnosis to imatinib was 7 mo (0 – 178) and 71% pts were early-imatinib treated. Prior therapy with interferon was used in 70% pts. The median of follow-up was 47 mo. Treatment interruption was observed in 63/185 patients (34%) and was related to toxicities in 35/63 pts (55%) and to nonadherence in 28/63 pts (45%). The adherence rate was 85%. In a multivariate analysis, only late-onset imatinib treatment (Odds Ratio [OR]=36,05; p<0,001) and severe comorbidity (OR=27,05; p=0,03) were associated with higher risk of interrupting imatinib for any reason. The only variable associated with nonadherence was late-onset imatinib treatment (OR=14,76; p<0,001). Although not statistical significant, male and comorbidity showed a tendency to be linked with nonadherence (Table 1). Nonadherent pts, compared with adherent ones, had lower complete cytogenetic response (CCyR) rates at 12 mo (39% and 65%; p=0,004, respectively; Figure 1) and lower major molecular response (MMR) rates at 18 mo (9,5% and 35%; p=0,002, respectively; Figure 2). Finally, treatment interruption had a relevant negative impact on EFS in 4 yr. In the group that had treatment interruption, EFS was 52%, compared with 78,5% in the group without interruptions (p=0,002; Figure 3). Analysis performed only on nonadherence treatment interruption groups showed no significant difference (53% and 71%; p=0,15, respectively). Conclusions In this cohort, a substantial proportion of pts failed to take imatinib properly, decreasing the chances of disease control. The late onset of imatinib therapy correlates with lower adherence, so front-line imatinib therapy should be started as soon as possible. Special attention should be given to pts with severe comorbidities, as they are more prone to suffer side effects or to lack adherence. Finally, pts who interrupted treatment had lower CCyR, MMR and EFS. Clinical and patient characteristics related to nonadherence Disclosures: No relevant conflicts of interest to declare.

Objetivo: Avaliar os benefícios na percepção de qualidade de vida (QV) de mulheres portadoras de câncer de mama relacionado à posse de animais de estimação e da vivência de atividade de lazer. Métodos: Estudo transversal comparando a QV entre as pacientes, mediante a aplicação do Questionário WHOQOL-Bref. Participaram da pesquisa 272 mulheres diagnosticadas com câncer de mama. Resultados: As pacientes tutoras de animais de estimação (n=162) obtiveram melhores médias de QV na percepção de QV global (72,45 vs. 67,16; p=0,01) e nos domínios meio ambiente (67,52 vs. 64,23; p=0,04) e psicológico (70,29 vs. 66,44; p=0,03) quando comparadas as não tutoras de animais de estimação (n=110). Ainda, aquelas que afirmaram realizar atividade de lazer (n=214) obtiveram melhores médias de QV na percepção de QV global (72,43 vs. 62,50; p<0,001)

4423 Background Treatment of chronic myeloid leukemia with imatinib leads to disease remission in a majority of patient, but in some patients (pts) controlling the disease remains a challenge. One of the proposed prognostic factors for identifying this subset of pts is the treatment response in the first months of therapy. Objectives We conducted a study to evaluate the importance of the early complete cytogenetic response (CCyR) and the factors associated with its achievement. Methods This is a retrospective study in a cohort of pts with chronic-phase chronic myeloid leukemia (CP-CML) enrolled in 14 Hematology centers in South Brazil. All pts received imatinib 400mg as first or second-line therapy. Early-imatinib treatment was considered when imatinib started before 12 months (mo) from diagnosis. Patient evaluation and response criteria followed the ELN recommendations. The ACE-27 (Adult Comorbidity Evaluation-27) is a 27 item comorbidity index for patients with cancer and assign weights from 1 to 3 based on the dysfunction grade of each condition (mild, moderate and severe, respectively). An ACE-27 score was applied to each patient. Imatinib suspensions were considered if superior to 20 days at any point during therapy. EFS was measured from the start of imatinib to the date of any of the following events while on therapy: death from any cause, loss of complete hematologic response, loss of complete cytogenetic response, discontinuation of therapy for toxicity or lack of efficacy, or progression to accelerated phase or blastic phase. Results We analyzed data from 450 pts with CP-CML diagnosed since 1990. The median age at diagnosis was 48 yr (4 – 85) and 55% were male. The median time from diagnosis to imatinib was 7 mo (0 – 178) and 71% pts were early-imatinib treated. Prior therapy with interferon was used in 60% pts. The median of follow-up was 47 mo. With 6 months of imatinib therapy, 198 pts (44%) achieved CCyR. In this group, the four year cumulative incidence of events was 33 (17%) and the EFS was 75,5%. 252 (56%) were not in CCyR at 6 months of therapy. In this group, a greater proportion of cumulative of events was observed: 86 (34%), and the EFS was 62,3%. This difference was significant (P=0,03; Figure 1). In this group of pts, 63% achieved CCyR after 6 months any time during follow up and the median time for CCyR in these pts was 17 months. The chance of achieving major molecular response (MMR) during follow up was 79% for the pts with CCyR at 6 months compared to 53% for the group with no CCyR at 6 months (P<0,001). Some factors were associated with reduced chance of CCyR at 6 months. In a multivariate analysis, the pts with late-onset imatinib treatment (more than 12 mo from diagnosis) had a CCyR rate of 31%, in contrast, the pts who started imatinib before 12 mo had a rate of 50% (P=0,02). The pts with good adherence to treatment had greater CCyR rate than those with poor adherence (interruption greater than 20 days), 51,4% and 35%, respectively (P=0,04). Comorbidity measured by ACE-27 score also influenced the CCyR rates at 6 months: 54% of score 0 (no comorbidity) patients achieved CCyR, compared to 30% of pts with score 1 (mild comorbidity), 33% of pts with score 2 (moderate) and 47% of pts with score 3 (severe) (P=0,009). The greater CCyR rate in the severe comorbidity group probably lacks significance due to the reduced number of pts in this group (22). Conclusions A great proportion of pts achieve CCyR after 6 months of imatinib therapy, nevertheless, the pts who achieve CCyR by 6 months of therapy have greater proportion of major molecular response and event-free survival. Imatinib therapy should be started as soon as possible and additional efforts must be taken to avoid nonadherence. Finally, special attention should be given to pts with comorbidities as their results tend to be worse. Disclosures: No relevant conflicts of interest to declare.

mente (p <0,001) o uso de CHs, diminuindo os riscos aos quais os pacientes poderiam estar expostos. (p < 0.001). Rev. bras. hematol. hemoter. 2008; 30(4):333-334. Abstract This study describes the impact of the implantation of a document of responsibility that should be followed by doctors who do not comply with the guidelines of Hospital de Clínicas when prescribing packed red blood cells. Data analysis shows that the compulsory nature of the responsibility terms significantly decreases the number of packed red blood cells transfused in opposition to the Institution guidelines

Background Monitoring response to TKI therapy is one of the key management strategies of chronic myeloid leukemia (CML). Early molecular response to first-line TKI therapy is emerging as an effective prognostic factor indicator of long-term durable response and survival. Objectives We conducted a study to evaluate the importance of the early molecular response (EMR) at 3, 6 and 12 months (mo), and 3-year event free survival (EFS). Methods This is a retrospective study in a cohort of pts with chronic myeloid leukemia chronic phase (CP) enrolled in 14 Hematology centers in South Brazil. All pts received imatinib 400mg as first or second-line therapy. Patient evaluation and response criteria followed the ELN recommendations. EFS was measured from the start of imatinib to the date of any of the following events while on therapy: death from any cause, loss of complete hematologic response, loss of complete cytogenetic response, discontinuation of therapy for toxicity or lack of efficacy, or progression to accelerated phase or blastic phase. Results We analyzed data from 517 pts with CML-CP diagnosed since 1990. After a median observation time of 46 months, 5-year overall survival (OS) was 86% and 5-year event-free-survival was 53%. At 3 mo, EFS was 72,5% for 46 pts with BCR-ABLIS ≤10% compared to 58% for 14 pts with BCR-ABLIS >10% (p<0,07). Similarly, when EMR was analysed at 6 mo, the EFS was 81% for 75 pts with BCR-ABLIS ≤1%, while 31% of EFS was achieved for 38 pts with BCR-ABLIS >1% (p<0,001). At 12 mo, the 3-year EFS was 86% for 65 pts with with BCR-ABLIS ≤0,1% compared to 54% for pts with BCR-ABLIS>0,1% (p<0,001). Conclusions A significant proportion of pts achieve ERM after 3,6 and 12 mo of imatinib therapy with better 3-year EFS. ERM may could identify those pts more likely to have a favorable outcome. Disclosures No relevant conflicts of interest to declare.